In addition, the efficacy of Ustekinumab, a human anti-IL-12/23 p40 monoclonal antibody and human anti-IL-23 monoclonal antibody, Guselkumab, has been evaluated in patients with active RA not responsive to methotrexate therapy. This evidence concerns the gene IL37 and rheumatoid arthritis.